Precision’s Snider Interviewed by AJMC Regarding New CAR-T Societal Value Study
A new Precision Health Economics-authored study on the societal value of CAR-T therapy is generating a significant level of interest within the scientific community. PHE’s Julia Snider touches on some of the key takeaways of the study, presented at this year’s ASH, with the American Journal of Managed Care.
To read the complete article including Julia’s comments, please click here.
By: Jason Shafrin, PhD Sr. Director, Policy and Economics and Jacki Chou, MPL Senior Director, Policy and Economics The recent announcement that CVS Caremark will use value-based metrics to inform formulary design at first appears a step in the right direction. However, using value measurements from a single nongovernmental organization—the Institute for Clinical and Economic Review (ICER)—based on a limited picture of treatment value may be problematic. Using this single assessment of value in an effort solely to exclude drugs from a major insurance formulary is even more worrisome and fails to recognize the heterogeneity in patient clinical needs and preferences.